leadf
logo-loader
viewTetra Bio-Pharma

Tetra Bio-Pharma inks research deal to study ARDS-003 in coronavirus animal model

The research collaboration will evaluate the company’s drug ARDS-003, with and without antiviral drugs, to prevent and treat SARS-CoV-2

Scientist wearing PPE using a microscope
Tetra has previously studied the effects of ARDS-003 in an animal model of a lung injury known as induced pulmonary fibrosis

Tetra Bio-Pharma (TSE:TBP) (OTCQB:TBPMF) (FRA:JAM1) has signed a research collaboration agreement with Targeted Pharmaceutical Inc and the George Mason University National Center for Biodefense and Infectious Diseases (NCBID), the company announced Thursday. 

The research collaboration will evaluate the company’s drug ARDS-003, with and without antiviral drugs, to prevent and treat SARS-CoV-2 (the virus that causes COVID-19) in animals. Leading the effort is Lance Liotta, the chief medical officer of Targeted Therapeutics and a professor at George Mason. 

Tetra owns a 20% minority stake in Targeted Pharmaceutical, which it announced last quarter.

READ: Tetra Bio-Pharma gets global rights to Adversa mucoadhesive technology for its Dronabinol drug from IntelGenx

"We have initiated this research agreement to generate new intellectual property and work closer with key researchers in the USA who are investigating therapeutic agents for treatment of patients who are severely ill from COVID-19,” Tetra CEO Guy Chamberland said in a statement. “Teaming up with Targeted Pharmaceutical opened the door to a collaboration with a prestigious USA research laboratory at the George Mason University.” 

Tetra has previously studied the effects of ARDS-003 in an animal model of a lung injury known as induced pulmonary fibrosis. The drug was able to reduce the levels of key inflammatory cytokine markers.

“Having the ability to study investigational new drugs in animals who are infected with the COVID-19 virus is a major opportunity for us,” Chamberland said. “The research team will gain tremendous knowledge on the role a cytokine release modulating drug plays in COVID-19 infections. This type of animal research was used to study potential drug candidates for Middle East Respiratory Syndrome (MERS-CoV) and most recently the REGN-COV2 antibody in SARS-CoV-2 infected animals."

The Ottawa-based company said it is not making any implied claims that its product has the ability to eliminate, cure and/or contain the COVID-19 at this time.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: Tetra Bio-Pharma

Price: 0.18 CAD

TSX:TBP
Market: TSX
Market Cap: $50.73 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tetra Bio-Pharma named herein, including the promotion by the Company of Tetra Bio-Pharma in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Tetra Bio-Pharma new CFO discusses recent pipeline advancements and company...

Tetra Bio-Pharma Inc (TSE:TBP)(OTCQB:TBPMF) CFO Jean-François Boily tells Proactive how the leader in cannabinoid-derived drug discovery is progressing on some of its advancing programs. Boily says the group completed mapping of human cannabinoids and metabolites during the third quarter of...

1 week, 5 days ago

2 min read